[ Ссылка ]


After fighting through chemotherapy, radiation or other treatments, the recurrence of cancer can be a bummer. But a new approach to hormone therapies might give doctors and patients a leg up.

Research presented at the American Society of Clinical Medicine indicated that extending the length of anti-estrogen hormone therapy decreased the risk of breast cancer recurrence.

A type of breast cancer known as hormone receptor-positive breast cancer is driven by the hormones estrogen, progesterone or both. As part of the treatment, women with this kind of breast cancer typically receive medications called aromatase inhibitors, which help reduce levels of estrogen. Many patients also receive a medication called tamoxifen which also reduces estrogen.

свернуть